Literature DB >> 34551594

Ranking Important Factors for Using Postoperative Chemotherapy in Nonmuscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).

Clint Cary1,2, Yan Tong3, Susan Linsell4, Khurshid Ghani4, David C Miller4, Michael Weiner2,5, Michael O Koch1, Susan M Perkins3, Gregory Zimet6.   

Abstract

PURPOSE: National and international guidelines recommend the use of 1 dose of intravesical chemotherapy immediately following surgery for nonmuscle invasive bladder cancer, which is performed infrequently on a population level. We sought to understand the importance of potential environmental and clinical dimensions involved in the decision to offer this therapy.
MATERIALS AND METHODS: Urologists from the Michigan Urological Surgery Improvement Collaborative (MUSIC) rated 8 distinct clinical vignettes involving patients with nonmuscle invasive bladder cancer. A ratings-based conjoint analysis method was used to evaluate the clinical vignette responses. Each vignette included 4 clinical dimensions and 2 environmental dimensions, with each dimension consisting of 2 possible attributes. The relative importance of each attribute was derived from the regression model and ranked in order.
RESULTS: A total of 58 urologists answered the clinical vignettes which represents >75% of MUSIC sites. The median age of urologists was 53, most were male, and median years in practice was 20 years post residency. An environmental attribute, having a recovery room protocol for instilling and disposing of the chemotherapy, ranked as the most influential attribute for giving postoperative chemotherapy (utility=8.6). The clinical attribute yielding the strongest preference for giving chemotherapy was tumor grade (utility=4.9). These preferences varied by different subgroups of urologists, particularly regarding the type of practice a urologist was in.
CONCLUSIONS: This study demonstrates that urologists have clear preferences for when they offer postoperative immediate chemotherapy. Factors beyond just clinical variables play a role in this decision making process such as the structure of the recovery room.

Entities:  

Keywords:  drug therapy; urinary bladder neoplasms

Mesh:

Year:  2021        PMID: 34551594      PMCID: PMC8741637          DOI: 10.1097/JU.0000000000002233

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Comparison of Rating Scale, Time Tradeoff, and Conjoint Analysis Methods for Assessment of Preferences in Prostate Cancer.

Authors:  Robert M Kaplan; Catherine M Crespi; Ely Dahan; Josemanuel D Saucedo; Casey Pagan; Christopher S Saigal
Journal:  Med Decis Making       Date:  2019-09-26       Impact factor: 2.583

2.  Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.

Authors:  Diane D Lu; Stephen A Boorjian; Jay D Raman
Journal:  Urol Oncol       Date:  2016-11-22       Impact factor: 3.498

3.  National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer.

Authors:  Michael S Cookson; Sam S Chang; Michael G Oefelein; Jack R Gallagher; Brent Schwartz; Kylee Heap
Journal:  J Urol       Date:  2012-03-14       Impact factor: 7.450

4.  The influence of resuscitation preferences on obstetrical management of periviable deliveries.

Authors:  B Tucker Edmonds; F McKenzie; K S Hendrix; S M Perkins; G D Zimet
Journal:  J Perinatol       Date:  2014-09-25       Impact factor: 2.521

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer.

Authors:  Daniel A Barocas; Alice Liu; Frank N Burks; Ronald S Suh; Timothy G Schuster; Timothy Bradford; Don A Moylan; Peter M Knapp; Daniel S Murtagh; David Morris; Rodney L Dunn; James E Montie; David C Miller
Journal:  J Urol       Date:  2013-06-18       Impact factor: 7.450

Review 7.  Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

Authors:  Richard J Sylvester; Willem Oosterlinck; Sten Holmang; Matthew R Sydes; Alison Birtle; Sigurdur Gudjonsson; Cosimo De Nunzio; Kikuo Okamura; Eero Kaasinen; Eduardo Solsona; Bedeir Ali-El-Dein; Can Ali Tatar; Brant A Inman; James N'Dow; Jorg R Oddens; Marek Babjuk
Journal:  Eur Urol       Date:  2015-06-16       Impact factor: 20.096

8.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

9.  Barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer: what's the problem?

Authors:  Clint Cary; Laura Militello; Paige DeChant; Richard Frankel; Michael O Koch; Michael Weiner
Journal:  Urol Pract       Date:  2021-03-01

10.  A conjoint analysis study on self-sampling for human papillomavirus (HPV) testing characteristics among black women in Indiana.

Authors:  Erika Biederman; Victoria Champion; Gregory Zimet
Journal:  BMC Womens Health       Date:  2020-03-19       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.